STAT+: The health tech tracker for the second quarter: 15 pivotal industry events to watch
Securing a billion dollars of yearly funding was once considered a landmark achievement in health…
Category: STAT+
STAT+: At BGI, China’s genomics giant, the line between biotech and Beijing is increasingly blurry
On Jan. 25, 2020, as the city of Wuhan headed into the world’s first Covid-19 lockdown,…
STAT+: The U.S. government doesn’t have patent rights to Gilead’s remdesivir, despite investing millions in research
American taxpayers may have provided $162 million toward researching the drug remdesivir, but the federal…
STAT+: Data for Delcath’s liver tumor device are positive, but lingering questions cloud path to approval
Delcath Systems said Wednesday that its liver-tumor treatment device achieved the primary goal of a…
.jpg)
STAT+: Pharmalittle: Pfizer says Covid-19 shot is safe and effective in adolescents; FTC wants to block another Illumina deal
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: The biotech scorecard for the second quarter: 18 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the second…
STAT+: FTC seeks to block Illumina from buying Grail, citing threats to competition
The Federal Trade Commission is once again trying to block Illumina, a dominant maker of…
STAT+: Most U.S. universities get an ‘F’ on ensuring access to drugs they discover
Despite large amounts of taxpayer funding, dozens of the largest U.S. universities failed to commit…
STAT+: Pharmalittle: Pfizer and BioNTech to boost Covid-19 vaccine production; lawmakers ask FTC to probe insulin pricing
Rise and shine, another busy day is on the way. There is a rhythm to…
A CRISPR 2.0 pioneer, expecting credit on its own invention, is ruffled by a competitor
Last week, the genome-editing scientists behind base editing, a technology dubbed CRISPR 2.0, gathered for…
STAT+: 5 health care projects to watch at Google Cloud
If the pieces come together, Google will be as omnipresent in health care as it…
STAT+: Here are the drug pricing policy options Democrats could use to pay for their next big legislative push
WASHINGTON — Democrats in Congress are already gearing up for their next big legislative push,…
STAT+: The operation formerly known as Warp Speed: Biden leans heavily on the flagship Trump-era initiative
WASHINGTON — The Biden White House has made no secret of its disdain for President…
STAT+: Canadian company pursues compulsory license to distribute Covid-19 vaccine to low-income countries
Twice in recent months, a small Canadian company has approached two large drug makers to…
STAT+: Humanigen says it drug keeps Covid patients off ventilators. But are some data missing?
A small biotech firm, Humanigen, said Monday that its experimental drug reduced the risk of…
STAT+: Congressional lawmakers urge FTC to investigate insulin makers over their pricing
In the latest flare up over the cost of insulin, several Congressional lawmakers want the…
STAT+: Pharmalittle: White House eyes suspending patent rights on Covid-19 vaccines; J&J supplier may be a vaccine bottleneck
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Uniqure investigation clears hemophilia B gene therapy as cause of patient’s liver cancer
Uniqure, the Dutch gene therapy company, said Monday that its one-time treatment for hemophilia B…
STAT+: The future of cancer immunotherapy: your questions, answered
Last week, I hosted an hourlong webinar on future directions for cancer immunotherapy. I focused…
STAT+: FDA approves first personalized cell therapy for patients with multiple myeloma
The Food and Drug Administration on Friday approved the first personalized cell therapy to treat…
STAT+: Canada says drug spending keeps rising due to increasingly expensive specialty meds
As Canadians brace for new rules to address prescription drug spending, a government report found…
.jpg)
STAT+: Pharmalittle: Novavax faces raw-materials shortages for Covid-19 shot; India curbs vaccine exports
And so, another working week will soon draw to a close. Not a moment too…
STAT+: With time running out, an ALS patient fights with Biogen over expanded access to its drug
Earlier this year, Lisa Stockman Mauriello was diagnosed with a fast-moving form of ALS, a…
STAT+: EPA rule that could help citrus growers is challenged over concerns about antibiotic resistance
Amid rising concern over antibiotic resistance, a coalition of advocacy groups has filed a lawsuit…
STAT+: FDA panel says risks of Pfizer pain drug outweigh the benefits
A panel of expert advisers to the Food and Drug Administration on Thursday concluded that…
STAT+: Broad Institute launches $300 million effort to harness AI to fight diseases
The Broad Institute of MIT and Harvard is launching a new, $300 million initiative that…
STAT+: Pharmalittle: AstraZeneca revises Covid-19 vaccine effectiveness; contractors grab a big slice of vaccine revenues
Good morning, everyone, and how are you today? The sun is trying to peek through…
STAT+: Behind the scenes, companies helping big Covid-19 vaccine makers are getting rich
Pfizer and Moderna aren’t the only vaccine money-makers. Much of the revenue and profits from…
STAT+: Pfizer hopes for a happy ending for an osteoarthritis drug with a troubled history
For more than a decade, Pfizer has run dozens of trials in hopes of eventually…
STAT+: With Amazon and Ro on its heels, Uber expands its prescription delivery business
After steering into prescription delivery in two cities last summer with digital pharmacy startup NimbleRx,…
STAT+: A ‘conditional’ EUA for a CytoDyn Covid treatment? FDA says no such thing exists
Speaking Monday night to investors on a conference call, CytoDyn CEO Nader Pourhassan said the…
STAT+: Pharmalittle: Europe moves to curb Covid-19 vaccine exports; Slaoui fired from Galvani board over sexual harassment claim
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
Opinion: STAT+: A Biden-Harris Biomanufacturing Initiative could increase supplies of vaccines, therapeutics in one fell swoop
The coronavirus pandemic is generating pressure on the manufacturing of vaccines and therapeutics. Every day…
STAT+: Senate reaches deal to extend Medicare pay bump for health care providers through 2021
WASHINGTON — Senate leaders have reached an agreement to extend a Medicare pay bump for…
STAT+: After leading a corporate turnaround, a swashbuckling CEO flies AstraZeneca into turbulence
It took eight years, a failed hostile takeover, and a sweeping scientific turnaround for AstraZeneca…
STAT+: AbbVie accuses a company of recruiting an employee in order to steal Humira secrets
Two years ago, a manufacturing team leader at AbbVie (ABBV) took a similar job at…
STAT+: Amy Abernethy, deputy commissioner who aimed to amp up FDA’s tech knowhow, to leave post
Amy Abernethy, the number two official at the Food and Drug Administration, plans to depart…
STAT+: Pharmalittle: AstraZeneca may have used ‘outdated’ info about its Covid-19 shot; Democrats eye drug-pricing measures
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Lawmakers introduce a bill to prevent Sacklers from using bankruptcy ‘loophole’ to evade liability
In a move directed at the owners of Purdue Pharma, a pair of Democratic lawmakers…
STAT+: Pharmalittle: AstraZeneca says studies show its Covid-19 vaccine is 79% effective; rich countries created vaccine inequity
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Digital therapeutics startups are ready for more regulation, not less
Digital therapeutics companies are eager to show their work. Five days before President Biden took…
STAT+: Winners, losers, and in-betweeners: How pharma companies stacked up in the Covid-19 vaccine race
In the early stages of the race to develop Covid-19 vaccines, it wasn’t clear how…
STAT+: Microbiome company Finch Therapeutics begins trading publicly, quietly shuffles one of its executives
Microbiome company Finch Therapeutics is, officially, worth about $960 million. Shares in the company began…
STAT+: Pharmalittle: Some European countries to resume use of AstraZeneca Covid-19 shot; Senate confirms Becerra as HHS secretary
And so, another working week will soon draw to a close. Not a moment too…
STAT+: How the wave of telehealth SPACs during the pandemic could create a ‘perfect storm’ for investors
In little more than a year, telehealth has gone from a backwater of American health…
STAT+: Does a drug’s name affect how patients and doctors perceive it? The FDA wants to know
Drug makers may spend untold sums of money giving medicines zippy names. Now, regulators want…
STAT+: Antibiotic stewardship may be improving at U.S. hospitals, but new targets are still needed
Amid increasing concern over antibiotic resistance, a new analysis found that nearly 56% of the…
STAT+: AmerisourceBergen say-on-pay proposal squeaks by amid outrage over CEO compensation
In a rebuke to AmerisourceBergen (ABC), nearly half of its shareholders voted against a “say-on-pay”…
STAT+: Pharmalittle: Europe isn’t ruling out waiving IP rights for Covid-19 shots; AstraZeneca defends vaccine production process
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: New monkey model of Alzheimer’s disease may accelerate search for human treatments
Researchers reported Thursday that they have created a new model for studying treatments of Alzheimer’s…